Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Source: View publication →
In the DISCOVER trial, F/TAF was shown to be non-inferior to F/TDF for HIV pre-exposure prophylaxis in MSM and transgender women, while demonstrating a more favorable bone and renal safety profile.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DISCOVER trial established F/TAF (Descovy) as a highly effective, FDA-approved alternative to F/TDF (Truvada) for HIV PrEP in men who have sex with men and transgender women. Because F/TAF limits systemic tenofovir exposure while maintaining high intracellular active metabolite levels, it mitigates the bone loss and renal tubular toxicity associated with TDF. It is now widely preferred for individuals with baseline osteopenia/osteoporosis or renal impairment, though clinicians must weigh this against the potential for mild weight gain and lipid increases.
Historical Context
Since the landmark iPrEx trial and the 2012 FDA approval of Truvada (F/TDF), daily oral F/TDF remained the sole medication approved for HIV PrEP. However, TDF's established association with declines in bone mineral density and renal function raised concerns for lifelong prophylactic use in healthy populations. Tenofovir alafenamide (TAF), a targeted prodrug, had already replaced TDF in many HIV treatment regimens due to enhanced safety. DISCOVER was the pivotal phase 3 trial that demonstrated TAF's efficacy in the prevention setting, leading to the 2019 FDA approval of Descovy for PrEP (excluding those at risk from receptive vaginal sex).
Guided Discussion
High-yield insights from every perspective
How does the pharmacokinetic profile of tenofovir alafenamide (TAF) differ from tenofovir disoproxil fumarate (TDF), and how does this mechanism explain the improved bone and renal safety outcomes observed in the DISCOVER trial?
Key Response
TDF is converted to active tenofovir in the plasma, leading to higher circulating levels that can cause proximal tubule toxicity and bone mineral density loss. TAF is a prodrug primarily cleaved intracellularly (by Cathepsin A in lymphoid cells), resulting in a 90% lower plasma tenofovir concentration. This targeted delivery reduces off-target renal and bone toxicity while maintaining high intracellular concentrations of the active drug.
Given the non-inferiority of F/TAF to F/TDF demonstrated in DISCOVER, in which specific patient populations would you definitively choose F/TAF over F/TDF for PrEP, and when might F/TDF still be preferred?
Key Response
F/TAF is preferred for patients with pre-existing renal dysfunction (eGFR between 30-60 mL/min) or those with known osteoporosis/osteopenia. F/TDF is still preferred (or required) for populations not studied in DISCOVER, such as cisgender women at risk via vaginal sex, patients with significant dyslipidemia or weight gain concerns (as TDF has a lipid-lowering and weight-suppressive effect compared to TAF), or when cost/generic availability is the primary barrier.
The DISCOVER trial highlighted improvements in bone and renal parameters for F/TAF, but how should we weigh the metabolic differences—such as weight gain and lipid profile changes—observed with TAF when discussing long-term cardiovascular risk in an aging PrEP population?
Key Response
While F/TAF avoids the well-documented renal and bone toxicity of F/TDF, patients transitioning to or initiating TAF often see a relative increase in weight and atherogenic lipids (partially due to the loss of TDF's statin-like effect). A nuanced fellow-level approach requires balancing these competing toxicities: mitigating osteo/renal issues versus potentially exacerbating metabolic syndrome and cardiovascular risk, necessitating individualized cardiovascular risk stratification for patients on lifelong PrEP.
When educating junior clinicians on the DISCOVER trial, how do you contextualize the clinical significance of the statistically significant but absolute small changes in eGFR and bone mineral density between F/TAF and F/TDF, particularly in light of healthcare economics and generic availability?
Key Response
An attending must bridge clinical trial statistics with real-world practice. While DISCOVER showed statistically significant bone/renal benefits for F/TAF, the absolute event rates for fractures or clinical renal failure in young, healthy MSM on F/TDF are exceptionally low. Teaching points should focus on high-value care: avoiding routine switching to expensive branded F/TAF for healthy, asymptomatic patients while appropriately reserving it for those with genuine risk factors, thus stewarding healthcare resources.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DISCOVER trial utilized a non-inferiority margin based on retaining a specific percentage of the historical efficacy of F/TDF compared to placebo. How does the unexpectedly low overall incidence rate of HIV in both study arms challenge the statistical power, margin selection, and interpretation of non-inferiority in modern prevention trials?
Key Response
In highly effective prevention trials, event rates (HIV infections) are extremely low. A PhD critique examines how the prespecified non-inferiority margin behaves when baseline incidence is lower than anticipated. Extremely low event rates make it difficult to rule out a clinically meaningful relative loss of efficacy without massive sample sizes, highlighting the fragility of confidence intervals and the challenge of proving non-inferiority when the denominator of events approaches zero.
As a peer reviewer evaluating the DISCOVER trial, what major concerns would you raise regarding the study's generalizability due to its exclusion criteria, and how does this limit the sweeping label indications of F/TAF for universal PrEP?
Key Response
A critical reviewer would flag the homogeneity of the trial population, which exclusively studied MSM and transgender women. Because tenofovir concentrations differ drastically across tissue types (e.g., cervicovaginal vs. rectal tissues), establishing non-inferiority in rectal exposure does not guarantee efficacy for vaginal exposure. Reviewers must demand strict caveats in the manuscript preventing off-label extrapolation to cisgender women or persons injecting drugs.
How does the evidence from the DISCOVER trial inform the CDC and WHO PrEP guidelines regarding the strength of recommendation for F/TAF, and what specific demographic and exposure-route limitations must the guidelines explicitly codify when outlining first-line regimens?
Key Response
Based on DISCOVER, current CDC guidelines recommend F/TAF as an FDA-approved PrEP option with a strong level of evidence (Level IA) but explicitly restrict this recommendation to MSM and transgender women. Guidelines must explicitly codify that F/TAF is NOT recommended for people at risk through receptive vaginal sex due to a lack of efficacy data in this compartment. The committee must position generic F/TDF as the universal first-line option across all demographics, with F/TAF as an alternative for specific populations.
Clinical Landscape
Noteworthy Related Trials
iPrEx Trial
Tested
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) daily
Population
HIV-negative men or transgender women who have sex with men
Comparator
Placebo
Endpoint
Incident HIV infection
IPERGAY Trial
Tested
On-demand (event-driven) Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Population
High-risk men who have sex with men
Comparator
Placebo
Endpoint
Incident HIV infection
HPTN 083 Trial
Tested
Long-acting injectable cabotegravir (CAB-LA) every 8 weeks
Population
Cisgender men and transgender women who have sex with men
Comparator
Daily oral Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Endpoint
Incident HIV infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis